- Recruiting
NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM
Updated: May 25, 2022
NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT04772989
Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
First Posted : February 26, 2021